(Total Views: 241)
Posted On: 11/24/2020 2:11:45 PM
Post# of 36519
Buildit, how many times does this need to happen? This brings into question the Bintai deal by just looking at their current business models, revenues and company net worth. We may have done a deal with a company that does not have the means to complete the trials, etc. So when hoops asked about SPAC, it brings up the authenticity of prior deals.
https://storage.googleapis.com/wzukusers/user...5_2019.pdf
Generex Biotechnology Announces Merger with Public Vehicle for Public
Trading of NuGenerex Immuno-Oncology
https://storage.googleapis.com/wzukusers/user...5_2019.pdf
Generex Biotechnology Announces Merger with Public Vehicle for Public
Trading of NuGenerex Immuno-Oncology
Quote:
Generex Biotechnology Corporation
(www.generex.com) (OTCQB:GNBT) today announced a merger transaction with a public
company that is DTC eligible and current with its SEC filings to serve as a vehicle for the
quotation of the common stock of its subsidiary NuGenerex Immuno-Oncology (NGIO) as
an independent, publicly traded company. Generex is in the process of finalizing its
annual report on Form 10-K, which will be filed in the coming days . The Form 10-K will
include the audited financial statements for the legal documentation and Super Form 8-
K filing for the merger of NGIO with the public vehicle. We expect that NuGenerex
Immuno-Oncology will be quoted on a public exchange by the end of November , and the
1:4 shareholder dividend that was paid to Generex shareholders in February 2019 will be
converted into public shares shortly thereafter.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.